LI Mei (US),ЛИ, Мей (US),PARALKAR Vishwas Madnav (US),ПАРАЛКАР, Вишвас Мадхав (US),PONS Jaume (US),ПОНС, Джоуми (US),STONE Donna Marie (US),СТОУН, Донна Мари (US),LI MEI,ЛИ, Мей,PARALKAR VISHWAS MADNAV,ПАРАЛКАР, Вишвас Мадхав,PONS JAUME,ПОНС, Джоуми,STONE DONNA MARIE,СТОУН, Донна Мари
申请号:
RU2011145435/10
公开号:
RU0002548817C2
申请日:
2010.05.10
申请国别(地区):
RU
年份:
2015
代理人:
摘要:
FIELD: medicine.SUBSTANCE: invention refers to immunology. Presented are anti-Dickkopf 1 (anti-Dkk-1) antibodies and their functional fragments specified among the antibodies: 1) containing CDR1 VH containing the amino acid sequence SSYAIS, SYAIS or GFTFSSY; CDR2 VH containing the amino acid sequence SVSGTGLGFGTYYPDSVKG or SVSGTGLGFGTY; and CDR3 VH, containing the amino acid sequence TSLENYAFDY or SLENYAFDY; and CDR1 VL containing the amino acid sequence RASESVDDFGISFIN; CDR2 VL containing the amino acid sequence AGSKQGS; and CDR3 VL containing the amino acid sequence QQLKEVPPT; and 2) the antibodies disclosed in Table 4 presented in the application materials. Described are: nucleic acids coding the above antibodies or their functional fragments; expression vectors containing the above nucleic acids; and cells used for expression of the above antibodies or their functional fragments and containing the above expression vectors. Presented is a method for producing the antibody or its functional fragment involving the stage of culturing the above expression cell. Disclosed is a composition possessing Dkk-1 binding activity, containing the antibody or its functional fragment in a therapeutically effective amount and a pharmaceutically acceptable excipient, thinner or carrier.EFFECT: invention enables extending the range of products for treating the diseases associated with Dkk-1 and LRP5/6 excessive reaction, which cause Wnt activation.14 cl, 14 dwg, 14 tbl, 6 exИзобретение относится к области иммунологии. Представлены антитела и их функциональные фрагменты против Dickkopf 1 (Dkk-1), которые выбраны из антител: 1) содержащего CDR1 VH, содержащий аминокислотную последовательность SSYAIS, SYAIS или GFTFSSY; CDR2 VH, содержащий аминокислотную последовательностьSVSGTGLGFGTYYPDSVKG или SVSGTGLGFGTY; и CDR3 VH, содержащий аминокислотную последовательность TSLENYAFDY или SLENYAFDY; и CDR1 VL, содержащий аминокислотную последовательностьRASESVDDFGISFIN; CDR2 VL, содержащий ам